Download PDF

1. Company Snapshot

1.a. Company Description

HCW Biologics Inc., a preclinical stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases.The company's lead products include HCW9218, which is an injectable immunotherapeutic for patients with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as pulmonary fibrosis; and HCW9302 for auto-immune diseases, such as alopecia areata and metabolic diseases.It also develops HCW9201, a cell-based therapy that is in Phase II clinical trials for the treatment of patients with relapsed/refractory acute myeloid leukemia; and HCW9206 for the treatment of acute myeloid leukemia.


The company was incorporated in 2018 and is headquartered in Miramar, Florida.

Show Full description

1.b. Last Insights on HCWB

Recent negative drivers behind HCW Biologics Inc.'s stock performance include the receipt of a NASDAQ Staff Determination Letter, indicating the company's failure to regain compliance with continued listing requirements. This notice, received on December 17, 2024, has likely weighed on investor sentiment. While the company was granted an extension by the Nasdaq Hearings Panel to regain compliance, the uncertainty surrounding its listing status remains a concern. Additionally, the lack of recent earnings releases and updates on the company's financial performance has contributed to the uncertainty.

1.c. Company Highlights

2. Transcript Summary

Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.

Request Coverage

3. NewsRoom

Card image cap

HCW Biologics (NASDAQ:HCWB) Trading Down 7.1% – Here’s What Happened

Dec -02

Source: defenseworld.net

Card image cap

HCW Biologics Announces Initiation of First-In-Human Clinical Trial to Evaluate HCW9302 in an Autoimmune Disease

Nov -18

Source: globenewswire.com

Card image cap

HCW Biologics Reports Third Quarter 2025 Business Highlights and Financial Results

Nov -14

Source: globenewswire.com

Card image cap

HCW Biologics Presents Preclinical Data for TRBC-Based T-Cell Engager Program at the Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting

Nov -07

Source: globenewswire.com

Card image cap

HCW Biologics to Participate in the 2025 Maxim Growth Summit

Oct -16

Source: globenewswire.com

Card image cap

HCW Biologics Inc. (NASDAQ: HCWB) Participates in Virtual Investor “What This Means” Segment About its Proprietary T-Cell Engager Program

Sep -30

Source: globenewswire.com

Card image cap

HCW Biologics, a Shareholder of Wugen, Congratulates Wugen on Its Recent Successful Equity Financing

Sep -18

Source: globenewswire.com

Card image cap

HCW Biologics Designates One of Its Proprietary TRBC-Pembrolizumab-Based Immune Checkpoint Inhibitors as its Franchise Immunotherapeutic for Internal Clinical Development

Sep -16

Source: globenewswire.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (10.27%)

6. Segments

Novel Immunotherapies

Expected Growth: 10.27%

HCW Biologics Inc.'s novel immunotherapies are driven by increasing demand for cancer treatments, advancements in gene editing technologies, and growing investments in R&D. The company's innovative pipeline, strategic partnerships, and expanding market share in the immunotherapy space contribute to its 10.27% growth.

7. Detailed Products

Immunotherapies

HCW Biologics Inc. offers a range of immunotherapies that harness the power of the immune system to fight diseases. These therapies are designed to stimulate the body's natural defenses to target and eliminate cancer cells, infectious diseases, and other diseases.

Gene Therapies

HCW Biologics Inc. develops gene therapies that use genes to prevent or treat diseases. These therapies involve introducing a healthy copy of a gene into a person's cells to replace a faulty or missing gene.

Vaccine Development

HCW Biologics Inc. develops vaccines that prevent infectious diseases. These vaccines stimulate the immune system to produce antibodies that fight diseases.

Cell Therapies

HCW Biologics Inc. develops cell therapies that use living cells to prevent or treat diseases. These therapies involve introducing healthy cells into a person's body to replace damaged or diseased cells.

Antibody Therapies

HCW Biologics Inc. develops antibody therapies that use antibodies to target and eliminate disease-causing agents. These therapies involve introducing antibodies into a person's body to fight diseases.

8. HCW Biologics Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

HCW Biologics Inc. faces moderate threat from substitutes due to the presence of alternative biologics and biosimilars in the market.

Bargaining Power Of Customers

HCW Biologics Inc. has a diverse customer base, which reduces the bargaining power of individual customers.

Bargaining Power Of Suppliers

HCW Biologics Inc. relies on a few key suppliers for raw materials, which gives them some bargaining power.

Threat Of New Entrants

The biologics industry is highly regulated, and new entrants face significant barriers to entry, but HCW Biologics Inc. still faces a high threat from new entrants.

Intensity Of Rivalry

The biologics industry is highly competitive, and HCW Biologics Inc. faces intense rivalry from established players.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 32.40%
Debt Cost 4.39%
Equity Weight 67.60%
Equity Cost 9.19%
WACC 7.63%
Leverage 47.93%

11. Quality Control: HCW Biologics Inc. passed 1 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Cara Therapeutics

A-Score: 4.1/10

Value: 7.4

Growth: 1.1

Quality: 5.4

Yield: 0.0

Momentum: 10.0

Volatility: 0.7

1-Year Total Return ->

View Full Report
Stock-Card
Cardio Diagnostics Holdings

A-Score: 2.9/10

Value: 7.6

Growth: 4.1

Quality: 3.2

Yield: 0.0

Momentum: 2.0

Volatility: 0.7

1-Year Total Return ->

View Full Report
Stock-Card
HCW Biologics

A-Score: 2.8/10

Value: 8.0

Growth: 4.1

Quality: 4.9

Yield: 0.0

Momentum: 0.0

Volatility: 0.0

1-Year Total Return ->

View Full Report
Stock-Card
Sangamo Therapeutics

A-Score: 2.8/10

Value: 7.2

Growth: 3.3

Quality: 4.1

Yield: 0.0

Momentum: 2.0

Volatility: 0.3

1-Year Total Return ->

View Full Report
Stock-Card
Eyenovia

A-Score: 2.6/10

Value: 7.6

Growth: 4.8

Quality: 3.3

Yield: 0.0

Momentum: 0.0

Volatility: 0.0

1-Year Total Return ->

View Full Report
Stock-Card
Orchestra BioMed

A-Score: 2.2/10

Value: 6.0

Growth: 2.9

Quality: 3.6

Yield: 0.0

Momentum: 0.0

Volatility: 0.7

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

1.78$

Current Price

1.78$

Potential

-0.00%

Expected Cash-Flows